FY26 Annual Report and Appendix 4E
Filed with ASX · · 67 pages · English
Summary by 6ix AI
The report highlights a significant shift towards the development of a Female Testosterone Metered Dose Transdermal System, aimed at addressing unmet clinical needs in women's health. Despite an increase in total revenue, the company reported a notable loss for the period, reflecting challenges in its operations. The report also emphasizes Acrux's commitment to corporate governance and sustainability practices as part of its operational framework.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Acrux
- Investor Presentation - Female Testosterone for HSDD
- Update - Licensing Lenzetto for Australia for AUD5.4m
- Acrux licenses Lenzetto for Australian market for AUD5.4m
- Capital Gains Tax exemptions remain in place for Acrux
- Acrux raises $1.6 million via Share Placement
Later from Acrux
- Acrux has received $1.977m RDTI rebate for FY26
- FDA clears regulatory pathway for Female Testosterone MDTS
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux